StreetAlpha.app
Home › Stocks › GRFS

Grifols SA (GRFS)

$8.15
▼ −0.61%
LAST CLOSE · NOV 20

Grifols makes medicines derived from human plasma and diagnostic products for hospitals, clinics and laboratories. It last closed at $8.15 on Nov 20, down 0.61% on the day.

AI Auto Pilots
Is GRFS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GRFS.

Key Stats

Fiscal 2024
Results
Revenue
EUR 7.2B
+9.4% vs a year ago
Net income
EUR 156.9M
+270.8% vs a year ago
Free cash flow
EUR 669.6M
9.3% margin
Gross margin
38.7%
EUR 2.8B gross profit
Balance sheet
Cash & equivalents
EUR 979.8M
At Dec 31
Shareholder equity
EUR 8.6B
ExchangeNasdaq
Financials history
FY2020: EUR 5.3BEUR 5.3BFY2020FY2021: EUR 4.9BEUR 4.9BFY2021FY2022: EUR 6.1BEUR 6.1BFY2022FY2023: EUR 6.6BEUR 6.6BFY2023FY2024: EUR 7.2BEUR 7.2BFY2024

From GRFS's SEC filings, latest 20-F for the period ending Dec 31, 2024 (filed Apr 17). Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on GRFS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GRFS

Technical Analysis

GRFS · as of the Nov 20 close · updated each morning
Turning up

The stock sits between its 20 and 50 day averages. It is 2% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the Pivot S1 at $8.08, and the nearest resistance the swing high (May 27) at $8.18.

Short trendBullish
Long trendNeutral
MomentumFading
StretchNormal
VolatilityNormal, 2.8%/day
Key levels
$9.7752 week high+19.9%
$8.4420 day average+3.6%
$8.23Pivot R1+1.0%
$8.18Swing high (May 27)+0.4%
$8.15Pivot+0.0%
$8.15Last close
$8.08Pivot S1−0.9%
$7.95200 day average−2.5%
$7.8250 day average−4.0%
$7.77100 day average−4.7%
$7.71Swing low (Jul 31)−5.4%
$6.9652 week low−14.6%
Indicators
RSI (14)46.55Middle of its rangeNeutral
MACD0.18Below its signal lineBearish
Stochastic19.8Near the bottom of its rangeOversold
ADX (14)32.7Trending down
Williams %R-91.4Oversold below −80, overbought above −20Oversold
CCI (20)-78.5Oversold below −100, overbought above 100Neutral
Rate of change−3.3%Change over 10 sessionsBearish
ATR (14)$0.23Typical daily range, 2.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for GRFS

What happened before

See how GRFS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow GRFS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How GRFS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for GRFSHow many large options trades hit GRFS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

GRFS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲86 buying vs 70 selling
  • ▼Shares held by funds -2.1%
  • ●Funds holding -1
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding167168−0.6%
In funds' top 10330.0%
Held by funds–––
New / increased18 / 6817 / 53+22.9%
Reduced / sold out50 / 2068 / 38−34.0%
Put/call ratio0.910.24+284.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GRFS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRFS is in one of them and how their past GRFS trades turned out.

GRFS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GRFS in an article yet. Here's the latest on the wider market.

GRFS Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Apr 17
Who traded GRFS · since 2019
Latest 4 filings
$1K – $15KTraded Mar 31, 2023Filed Apr 17, 2023
$1K – $15KTraded Feb 27, 2023Filed Mar 20, 2023
$1K – $15KTraded Jun 24, 2019Filed Apr 27, 2020
$100K – $250KTraded Nov 11, 2019Filed Dec 23, 2019
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KMar 31, 2023Apr 17, 202317 d
Dan GoldmanD · NYBuy$1K – $15KFeb 27, 2023Mar 20, 202321 d
Donna ShalalaD · FLSell$1K – $15KJun 24, 2019Apr 27, 2020308 d
Greg GianforteR · MTSell$100K – $250KNov 11, 2019Dec 23, 201942 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Grifols SA

Grifols makes medicines derived from human plasma, the liquid part of blood, and sells them to hospitals, clinics and healthcare providers. These therapies treat conditions such as immune deficiencies, hemophilia and emphysema linked to alpha 1 protein deficiency. The company also makes diagnostic tests and instruments for blood banks and clinical laboratories, along with infusion solutions and nutrition products for hospital use. It is based in New York and runs plasma collection centers to supply its manufacturing.

Headquarters
New York, NY